Janux Therapeutics, Inc. (JANX)
JANX Stock Price Chart
Explore Janux Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze JANX price movements and trends.
JANX Company Profile
Discover essential business fundamentals and corporate details for Janux Therapeutics, Inc. (JANX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jun 2021
Employees
91.00
Website
https://www.januxrx.comCEO
David Alan Campbell
Description
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Financial Timeline
Browse a chronological timeline of Janux Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.26, while revenue estimate is $19.07m.
Earnings released on 7 May 2026
EPS came in at -$0.39 surpassing the estimated -$0.52 by +25.03%, while revenue for the quarter reached $3.73m , missing expectations by -14.32%.
Earnings released on 26 Feb 2026
EPS came in at -$0.51 surpassing the estimated -$0.65 by +21.54%, while revenue for the quarter reached $7.88m , beating expectations by +9.36k%.
Earnings released on 6 Nov 2025
EPS came in at -$0.39 surpassing the estimated -$0.60 by +35.00%, while revenue for the quarter reached $10.00m .
Earnings released on 7 Aug 2025
EPS came in at -$0.55 falling short of the estimated -$0.48 by -14.58%.
Earnings released on 8 May 2025
EPS came in at -$0.38 surpassing the estimated -$0.43 by +11.63%.
Earnings released on 27 Feb 2025
EPS came in at -$0.36 surpassing the estimated -$0.49 by +26.53%.
Earnings released on 6 Nov 2024
EPS came in at -$0.51 falling short of the estimated -$0.37 by -37.84%, while revenue for the quarter reached $439.00k , missing expectations by -70.64%.
Earnings released on 7 Aug 2024
EPS came in at -$0.11 surpassing the estimated -$0.32 by +65.63%, while revenue for the quarter reached $8.90m , beating expectations by +513.59%.
Earnings released on 7 May 2024
EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%, while revenue for the quarter reached $1.25m , beating expectations by +89.70%.
Earnings released on 8 Mar 2024
EPS came in at -$0.25 surpassing the estimated -$0.37 by +32.43%, while revenue for the quarter reached $2.46m , beating expectations by +232.57%.
Earnings released on 7 Nov 2023
EPS came in at -$0.25 surpassing the estimated -$0.46 by +45.65%, while revenue for the quarter reached $2.52m , beating expectations by +326.61%.
Earnings released on 8 Aug 2023
EPS came in at -$0.42 surpassing the estimated -$0.52 by +19.23%, while revenue for the quarter reached $1.06m , beating expectations by +20.80%.
Earnings released on 9 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.49 by +14.29%, while revenue for the quarter reached $2.05m , beating expectations by +135.40%.
Earnings released on 10 Mar 2023
EPS came in at -$0.39 surpassing the estimated -$0.45 by +13.33%, while revenue for the quarter reached $2.85m , beating expectations by +324.63%.
Earnings released on 10 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.51 by +21.57%, while revenue for the quarter reached $1.81m , beating expectations by +129.49%.
Earnings released on 9 Aug 2022
EPS came in at -$0.41 falling short of the estimated -$0.37 by -10.81%, while revenue for the quarter reached $2.37m , beating expectations by +263.85%.
Earnings released on 10 May 2022
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%, while revenue for the quarter reached $1.59m , beating expectations by +96.08%.
Earnings released on 18 Mar 2022
EPS came in at -$0.33 falling short of the estimated -$0.30 by -10.00%, while revenue for the quarter reached $1.62m , beating expectations by +272.92%.
Earnings released on 9 Nov 2021
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $1.16m , beating expectations by +791.54%.
Earnings released on 10 Aug 2021
EPS came in at -$0.62 falling short of the estimated -$0.13 by -376.92%, while revenue for the quarter reached $482.00k , meeting expectations.
JANX Stock Performance
Access detailed JANX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
